Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication
Kladnik et al.,
Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2..,
Journal of Enzyme Inhibition and Medicinal Chemistry, doi:10.1080/14756366.2022.2108417 (Ex Vivo)
Ex Vivo study showing zinc pyrithione to be a potent inhibitor of SARS-CoV-2 entry and replication.
Kladnik et al., 9 Aug 2022, peer-reviewed, 9 authors.
Ex Vivo studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
2022, VOL. 37, NO. 1, 2158–2168
https://doi.org/10.1080/14756366.2022.2108417
RESEARCH PAPER
Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo
inhibition of SARS-CoV-2 entry and replication
sitob, Meritxell Genescab, Marko
Jerneja Kladnika, Ana Dolinara, Jakob Kljuna, David Pereab, Judith Grau-Expo
a
b
a
Novinec , Maria J. Buzon and Iztok Turel
a
Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia; bInfectious Diseases Department, Vall d’Hebron
Research Institute (VHIR), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, VHIR Task Force COVID-19, Barcelona, Spain
ABSTRACT
ARTICLE HISTORY
Zinc pyrithione (1a), together with its analogues 1b–h and ruthenium pyrithione complex 2a, were synthesised and evaluated for the stability in biologically relevant media and anti-SARS-CoV-2 activity. Zinc
pyrithione revealed potent in vitro inhibition of cathepsin L (IC50¼1.88 ± 0.49 mM) and PLPro
(IC50¼0.50 ± 0.07 mM), enzymes involved in SARS-CoV-2 entry and replication, respectively, as well as antiviral entry and replication properties in an ex vivo system derived from primary human lung tissue. Zinc
complexes 1b–h expressed comparable in vitro inhibition. On the contrary, ruthenium complex 2a and
the ligand pyrithione a itself expressed poor inhibition in mentioned assays, indicating the importance of
the selection of metal core and structure of metal complex for antiviral activity. Safe, effective, and preferably oral at-home therapeutics for COVID-19 are needed and as such zinc pyrithione, which is also commercially available, could be considered as a potential therapeutic agent against SARS-CoV-2.
Received 21 June 2022
Revised 23 July 2022
Accepted 27 July 2022
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit